A review of the presentation and outcome of sarcoidosis in coronavirus disease 2019
Background: In the setting of the current pandemic, concerns have arisen regarding the multisystemic involvement of sarcoidosis and the possible exacerbations in response to the exposure to severe acute respiratory syndrome coronavirus 2 virus(SARS-CoV-2).
Aim: This study aims to compare the differences in clinical presentation, management, and outcome of COVID-19 between patients with sarcoidosis and those in the general population.
Methods: A literature search was conducted by reviewing original research articles such as case reports, case series, observational studies, and questionnaire-based surveys published in Pubmed/Medline, Web of Science, and google scholar. Data from individual patients in case series and case reports have been pooled to create a data set that was compared with larger such cohorts obtained from several other observational studies.
Results: 27 patients were identified from 14 original articles. No significant differences were found in the clinical manifestations of patients with sarcoidosis presenting with COVID-19 as compared to the general population. The rate of hospitalization in our study was found to be 48.1%. The overall mortality in our study was 7.4%, which is higher than the global average of 2.1%.
Conclusion: Our observations have reinforced the hypothesis that the presence of additional medical comorbidities is associated with a higher risk of ICU admission. Furthermore, the presence of moderate to a severe limitation in pulmonary functions is an additional risk factor associated with increased hospital admissions and mortality in sarcoidosis. However, neither the diagnosis of sarcoidosis nor ongoing treatment with steroids, methotrexate, or other immunosuppressants was associated with a poorer prognosis in patients with sarcoidosis.
Relevance for patients: Patients with sarcoidosis must take added precautions to mitigate the risk of acquiring COVID-19 infection in view of the COVID-19-related mortality rate in this group of patients. Specifically, immunocompromised patients (on immunomodulator drugs and high dose steroids) have been found to have an increased risk of contracting COVID-19. Overall impact on prognostication and outcome in cases requiring hospitalization remains yet to be determined.
[1] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199-207.
[2] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
[3] Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance-United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020;69:759-65.
[4] Tisminetzky M, Delude C, Hebert T, Carr C, Goldberg RJ, Gurwitz JH. Age, Multiple Chronic Conditions, and COVID-19: A Literature Review. J Gerontol A Biol Sci Med Sci 2020. Online ahead of print. https://doi. org/10.1093/gerona/glaa320
[5] Mishra AK, George AA, Peter D. Annular Cutaneous Sarcoidosis with Systemic Involvement. J Family Med Prim Care 2017;6:660-2.
[6] Ungprasert P, Ryu JH, Matteson EL. Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis. Mayo Clin Proc Innov Qual Outcomes 2019;3:358-75.
[7] Baughman RP, Lower E, Buchanon M, Rottoli P, Drent M, Sellares J, et al. Risk and Outcome of COVID-19 Infection in Sarcoidosis Patients: Results of a Self-Reporting Questionnaire. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:e2020009.
[8] Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, et al. COVID-19 Pneumonia in a Large Cohort of Patients Treated with Biological and Targeted Synthetic Antirheumatic Drugs. Ann Rheum Dis 2021;80:e14.
[9] Gemcioglu E, Karabuga B, Ercan A, Erden A. A case of Inappropriate Antidiuretic Hormone Secretion Syndrome Associated with COVID-19 Pneumonia. Acta Endocrinol (Buchar) 2020;16:110-1.
[10] Ng MK, Ngo J, Patel A, Patel D, Ng KK. A Case Report of Rapidly Lethal Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019 Viral Pneumonia. Cureus 2020;12:e8228.
[11] Györfi AH, Kopp M, May M, Vetter M, Uder M, Kremer AE, et al. Glucocorticoid-Induced Relapse of COVID-19 in a Patient with Sarcoidosis. Ann Rheum Dis 2020. Epub ahead of print. http://dx.doi.org/10.1136/ annrheumdis-2020-218258
[12] Padala SA, Medepalli VM, Mohammed A, Vakiti A, Elam R, Gupta SJ. Management of Immunosuppression during Severe COVID-19 Infection in a Patient with Pulmonary and Cardiac Sarcoidosis. J Clin Rheumatol 2020;26:229-32.
[13] Yates PA, Newman SA, Oshry LJ, Glassman RH, LeoneAM, Reichel E. Doxycycline Treatment of High-Risk COVID19-Positive Patients with Comorbid Pulmonary Disease. Ther Adv Respir Dis 2020;14:1753466620951053. https:// doi.org/10.1177%2F1753466620951053
[14] Bénézit F, Le Bot A, Jouneau S, Lemaître F, Pronier C, Lentz PA, et al. COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020. Emerg Infect Dis 2020;26:2513-5.
[15] Manansala M, Ascoli C, Alburquerque AG, Perkins D, Mirsaedi M, Finn P, et al. Case Series: COVID-19 in African American Patients With Sarcoidosis. Front Med (Lausanne) 2020;7:588527.
[16] Kiani A, Razavi F, Bandegani N, Farahani M, Abedini A. Investigation of Sarcoidosis Patients during COVID-19 Pandemic. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:e2020015.
[17] Opoka LM, Wyrostkiewicz D, Winek J, Błasińska K, Miłkowska-Dymanowska J, Szturmowicz M. SARSCoV-2 Lung Disease in a Patient with Pulmonary Sarcoidosis-Case Report. Adv Respir Med 2020;88:620-5.
[18] Ramdani H, Benelhosni K, Billah NM, Nassar I. COVID-19 Pneumonia in a Patient with Sarcoidosis: A Case Report. Clin Case Rep 2021;9:910-3.
[19] Chopra S, Kaur J, Kaur M. Massive Pulmonary Embolism and Deep Vein Thrombosis in COVID-19 Pneumonia: Two Case Reports. Cureus 2021;13:e14833.
[20] Bajaj M, Saxena AK, Choudhary S, Jain S. Solicitous use of Injection Remdesivir, Tablet Baricitinib, and Plasma Therapy for Severe COVID-19 Patient Associated with Stage 4 Sarcoidosis and Type 2 Diabetes Mellitus: A Case Report. Indian J Case Rep 2021;7:307-9.
[21] van Dijck R, Lauw MN, Swinkels M, Russcher H, JansenAJ. COVID-19-Associated Pseudothrombocytopenia. EJHaem 2021;2:475-7.
[22] Jeny F, Lhote R, Lorillon G, Belhomme N, Pugnet G, Borie R, et al. Correspondence on Glucocorticoid-Induced Relapse of COVID-19 in a Patient with Sarcoidosis. Ann Rheum Dis 2020. Epub ahead of print. http://dx.doi. org/10.1136/annrheumdis-2020-218957
[23] Morgenthau AS, Levin MA, Freeman R, Reich DL, Klang E. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidosis Patients Infected with SARSCoV2. Lung 2020;198:771-5.
[24] Hadi YB, Lakhani DA, Naqvi SF, Singh S, Kupec JT. Outcomes of SARS-CoV-2 Infection in Patients with Pulmonary Sarcoidosis: A Multicenter Retrospective Research Network Study. Respir Med 2021;187:106538.
[25] Brito-Zerón P, Gracia-Tello B, Robles A, Alguacil A, Bonet M, De-Escalante B, et al. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses 2021;13:1000.
[26] Baughman RP, Lower EE. COVID-19 Infections in Sarcoidosis: A Prospective Single Center Study of 886 Sarcoidosis Patients. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021029.
[27] Desbois AC, Marques C, Lefèvre L, Barmo S, Lorenzo C, Leclercq M, et al. Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis. Clin Exp Rheumatol 2021. Online Ahead of Print.
[28] Sahu KK, Mishra AK, Martin K, Chastain I. COVID-19 and Clinical Mimics. Correct Diagnosis is the Key to Appropriate Therapy. Monaldi Arch Chest Dis 2020;90:1327. https://doi.org/10.4081/monaldi.2020.1327
[29] Momenzadeh M, Shahali H, Farahani AA. Coronavirus Disease 2019 Suspicion: A Case Report Regarding a Male Emergency Medical Service Pilot With Newly Diagnosed Sarcoidosis. Air Med J 2020;39:296-7.
[30] Calender A, Israel-Biet D, Valeyre D, Pacheco Y. Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. Trends Immunol 2020;41:856-9.
[31] Huang I, Pranata R. Lymphopenia in Severe Coronavirus Disease-2019 (COVID-19): Systematic Review and MetaAnalysis. J Intensive Care 2020;8:36.
[32] Behbahani S, Baltz JO, Droms R, Deng AC, Amano SU, Levin NA, et al. Sarcoid-Like Reaction in a Patient Recovering from Coronavirus Disease 19 Pneumonia. JAAD Case Rep 2020;6:915-7.
[33] Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients with Lung Cancer. J Thorac Oncol 2020;15:700-4.
[34] Del Giorno R, Iodice A, Mangas C, Gabutti L. New-Onset Cutaneous Sarcoidosis Under Tocilizumab Treatment for Giant Cell Arteritis: A Quasi-Paradoxical Adverse Drug Reaction. Case Report and Literature Review. Ther Adv Musculoskelet Dis 2019;11:1759720X1984179.
[35] Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. Front Cell Infect Microbiol 2020;10:317.
[36] Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. The Potential Role of Serum Angiotensin-Converting Enzyme in Coronavirus Disease 2019. BMC Infect Dis 2020;20:883.
[37] Tana C, Mantini C, Cipollone F, Giamberardino MA. Chest Imaging of Patients with Sarcoidosis and SARS-CoV-2 Infection. Current Evidence and Clinical Perspectives. Diagnostics (Basel) 2021;11:183.
[38] Lal A, Mishra AK, Sahu KK. CT Chest Findings in Coronavirus Disease-19 (COVID-19). J Formos Med Assoc 2020;119:1000-1.
[39] Criado E, Sánchez M, Ramírez J, Arguis P, de Caralt TM, Perea RJ, et al. Pulmonary Sarcoidosis: Typical and Atypical Manifestations at High-Resolution CT with Pathologic Correlation. Radiographics 2010;30:1567-86.
[40] Duzgun SA, Durhan G, Demirkazik FB, Akpinar MG, Ariyurek OM. COVID-19 Pneumonia: The Great Radiological Mimicker. Insights Imaging 2020;11:118.
[41] Mishra AK, Lal A, Sahu KK, Kranis M, Sargent J. Quantifying and reporting Cardiac Findings in Imaging of COVID-19 Patients. Monaldi Arch Chest Dis 2020;90:1394. https:/doi.org/10.4081/monaldi.2020.1394
[42] Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. Am J Roentgenol 2020;215:87-93.
[43] Mughal MS, Rehman R, Osman R, Kan N, Mirza H, Eng MH. Hilar Lymphadenopathy, a Novel Finding in the Setting of Coronavirus Disease (COVID-19): A Case Report. J Med Case Rep 2020;14:124.
[44] Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit Admission and Outcomes among Patients with Coronavirus: A Systematic Review and Meta-Analysis. PLoS One 2020;15:e0235653.
[45] Sweiss NJ, Korsten P, Syed HJ, Syed A, Baughman RP, Yee AM, et al. When the Game Changes. Chest 2020;158:892-5.
[46] van Paassen J, Vos JS, Hoekstra EM, Neumann KM, Boot PC, Arbous SM. Corticosteroid Use in COVID-19 Patients: A Systematic Review and Meta-Analysis on Clinical Outcomes. Crit Care 2020;24:696.
[47] Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in Sarcoidosis: The Relationship of Relapse to Corticosteroid Therapy. Chest 1997;111:623-31.
[48] Sahu KK, Mishra AK, Martin K, Chastain I. COVID-19 and Restrictive Lung Disease: A Deadly Combo to Trip off the Fine Balance. Monaldi Arch Chest Dis 2020;90:246-7.
[49] Southern BD. Patients with Interstitial Lung Disease and Pulmonary Sarcoidosis are at High Risk for Severe Illness Related to COVID-19. Cleve Clin J Med 2020. Online Ahead of Print. https://doi.org/10.3949/ccjm.87a.ccc026
[50] Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W, et al. Clinical, Serological, and Histopathological Similarities between Severe COVID-19 and Acute Exacerbation of Connective Tissue DiseaseAssociated Interstitial Lung Disease (CTD-ILD). Front Immunol 2020;11:587517.
[51] Panselinas E, Judson MA. Acute Pulmonary Exacerbations of Sarcoidosis. Chest 2012;142:827-36.
[52] Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 2020;202:1656-65.